Program
JNJ-87801493
A development code.
Its studies are mostly in Leukemia, Myeloid, Acute · Lymphoma, Non-Hodgkin, led by Johnson & Johnson.
Furthest: phase 1, since Nov 15, 20232 company-led studies, 2 open or runningNext primary completion: Jan 19, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 22 open or running | phase 1since Nov 15, 2023 | Nov 15, 2023 | Jan 19, 2028phase 1 · NCT06788509 |
- Named in Johnson & Johnson’s own pipeline as
JNJ-1493
, phase 1, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 15, 2023First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT06139406 · 70 enrolled · Australia, Denmark, Israel and more
- Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT06788509 · 120 planned · Australia, Belgium, Denmark and more
Ahead
- Jan 19, 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06788509
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more | 1 | By invitation | Jan 19, 2028 | 120 |
| NCT06139406Lymphoma, Non-Hodgkin · Australia, Denmark, Israel and more | 1 | Active, not recruiting | Jan 30, 2026 | 70 |
How it is read
Names in the registry
- “JNJ-87801493”, 2 entries
Codes read as this program: JNJ87801493.
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 1 study
- Lymphoma, Non-Hodgkin, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.